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Nonalcoholic steatohepatitis (NASH) is becoming common chronic liver disease because of the increasing
global prevalence of obesity and consequently Nonalcoholic fatty liver disease (NAFLD). However, the
mechanism for progression of NAFLD to NASH and then cirrhosis is not completely understood, yet. The
triggering of these hepatic diseases is thought from hepatocyte injury caused by over-accumulated lipid
toxicity. Injured hepatocytes release damage-associated molecular patterns (DAMPs), which can stimulate
the Kupffer cells (KCs), liver-resident macrophages, to release pro-inflammatory cytokines and chemokines,
and recruit monocyte-derived macrophages (MDMs). The increased activation of KCs and recruitment of
MDMs accelerate the progression of NAFLD to NASH and cirrhosis. Therefore, characterization for
activation of hepatic macrophages, both KCs and MDMs, is a baseline to figure out the progression of
hepatic diseases. The purpose of this review is to discuss the current understanding of mechanisms of
NAFLD and NASH, mainly focusing on characterization and function of hepatic macrophages and suggests
the regulators of hepatic macrophages as the therapeutic target in hepatic diseases.
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Non-alcoholic fatty liver disease (NAFLD) has emerged
as the most prevalent chronic liver disease worldwide,
affecting 20-30% of the general population [1]. The
identifying NAFLD is hepatic steatosis, which is
characterized by fat accumulation in more than 5% of
hepatocytes. Fat deposition is also caused by viral
infections, certain medications, and genetic disorders [2].
Nonalcoholic steatohepatitis (NASH) is a severe
progressed form of NAFLD. The pathological features
of NASH include hepatocellular damage and injury,
inflammation, and fibrosis and steatosis [3]. The incidence
of NASH is calculated to be 2-5% in the general
population and is considered as a significant risk factor
for hepatic cirrhosis and even hepatocellular carcinoma
(HCC).
Although NAFLD and NASH have been studied more
than 30 years, it is still not fully elucidated how they are
initiated and progressed. Initially, theory for the NASH
pathogenesis, two hit hypothesis, was proposed by Day
and James [4]. Simple steatosis, such as insulin sensitivity
(IR) and excessive fatty acid influx to the liver are two
important factors and is the first hit of NASH. Second hit
is that excess lipid accumulation in the liver results in
oxidative and ER stress, and lipotoxicity, which in turn
trigger mitochondrial dysfunction and hepatocyte injury.
They can stimulate inflammatory and wound healing
responses activate immune cells in liver [2]. The liver
has an abundance of macrophages, such as Kupffer cells
(KCs) and infiltrated macrophages, compared to other
organs. It is estimated there are 20-40 macrophages are
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supplementing every 100 hepatocytes [5]. They activate
hepatic stellate cells, which are the major source of liver
fibrosis [6]. As results, activation of inflammatory
macrophages and stellate cells promotes the progression
from steatosis to NASH [7].
Kupffer cells (KCs) are the resident macrophage in the
liver reside in liver sinusoids, the portal tract, and hepatic
lymph nodes [8]. In pathologic conditions, bone marrow-
derived monocytes, such as infiltrating macrophages
(monocyte-derived macrophages, MDM), migrate to the
liver and work in collaboration with KCs. However, the
difficulty in cellular experimental techniques, the
inflammatory responses and function of both KCs and
MDMs in the liver are not fully understood on NAFLD
and NASH progression.
In this Review, we focus on the discussion about the
current knowledge on the origins and composition of
hepatic macrophages, including KCs and MDMs, and
their involvement in both promoting and resolving liver
inflammation, injury, and fibrosis up to NASH.
Origin and composition of hepatic macrophages
Macrophages are a heterogeneous population of immune
cells and undertake for innate immune reactions with
diverse functions in tissue homeostasis and disease
progression and resolution [9]. They recognize, ingest,
and degrade cellular debris, foreign material, or pathogens
and exert a central function in orchestrating inflammatory
processes. However, macrophages employ a wide range
of different functions and consist of opposing cellular
subsets in the liver [10]. The diverse functions are
considered to be plasticity based on their cellular origin
and local microenvironment.
The hepatic macrophages have been characterized by
two populations; resident and infiltrating macrophages,
which are distinguished by ontogeny, phenotype, and
functional characterization [7]. Resident liver macrophages,
KCs reside in liver-specific and are self-renewing cells
which originated from embryonic progenitor cells
derived from the yolk sac. They are located in the liver
sinusoids in close contact with the liver sinusoidal
endothelial cells [11]. They play as first-line guardians,
against gut-derived microbiomes, pathogens or foreign
bodies. During hepatic damage and injury, they are also
assisted by infiltrating macrophages that originate from
blood circulating bone marrow-derived monocytes,
which call monocyte-derived macrophages (MDMs)
[12]. MDMs also play as a pro-inflammatory response,
whereas they could convert into alternative or opposing
state of activation.
In general, they can be divided either a classical
activation (pro-inammatory M1) or an alternative
activation (anti-inammatory M2) state by response to
different stimuli [13]. M1 is induced by lipopolysaccharides
(LPS) or interferon-γ and is associated with the
production of proinflammatory cytokines and chemokines.
M1-induced cytokines are important for host defense but
can induce tissue damage and immune cell activation in
the situation of chronic inflammation [14]. The
proinflammatory response is reduced by regulatory
macrophages (M2), which is induced by interleukin
(IL)-4/13, some Toll-like receptor (TLR) signaling
pathway, IL-10 or glucocorticoids. M2 produces cytokines
and growth factors, concerned in wound healing and
recovery from disease. Because they stimulate new
vessel and scar formation, M2-derived cytokines and
growth factors are essential for tissue remodeling and the
pathogenesis of chronic liver disease [13]. The M1 and
M2 subtypes represent the different polarization and
function states, which can be identified by specific
markers, such as M1 markers is peroxisome proliferator-
activated receptor (PPAR), CCL2, CX3CL1 and CCL5
whereas M2 markers is IL-4 receptor (IL-4R), mannose
receptor (MR/CD206), and arginase1 (Arg-1) [15,16].
These studies suggest that disruption of the M1/M2
balance could be effect on development, homeostasis
and diseases and regulation of polarization of macrophage
populations toward different phenotypes has been
implicated in clinical application. In addition, activation
and polarization of macrophages are deeply implicated
in the pathogenesis and progress in chronic liver
diseases, such as NAFLD and NASH.
Kupffer cells (KCs)
The liver is comprised by the hepatocyte, the most
numerous 60% of the total liver cells and 80% of the
volume of liver [17]. Twenty % of the liver cells include
sinusoidal endothelial cells KCs and hepatic stellate
cells. Approximately 15% of liver cells are KCs, the
resident macrophages of the liver, are the largest tissue
specific population of macrophages in the body [18].
KCs are located in liver sinusoids, the portal tract and
hepatic lymph nodes, which are the crossroads of the
portal vein and hepatic artery tributaries.
The main function of KCs in healthy liver is the
phagocytosis and presentation of pathogens from portal
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vein and arterial circulation, representing one of the first
lines of defense of the organism. Under normal
conditions, KCs express low levels of MHC (Major
Histocompatibility Complex) class II and co-stimulatory
molecules and then inhibit T cell activation [19]. KCs
also participate in immunosuppression by expressing
high amounts of T cell suppression molecules such as
IL-10 and TGF-β and low levels of costimulatory
molecules, which is critical for the induction of tolerance
to hepatocyte-expressed antigens [20-22]. Moreover,
KCs remove microbes, suggesting KCs are preserving
the hepatic area at optimally regulated stage of
inflammation [8]. For example, KC surface exhibits
TLRs, which are responsive to LPS, and produce and
secrete anti-inflammatory signals to respond to lipotoxicity,
including IL-10 in response to LPS [23].
The circumstance of NAFLD to NASH, various
metabolic syndromes and insulin resistance, could
induce accumulation of free fatty acids and lipids in
peripheral blood and hepatocytes, and could stimulate
innate immune responses that result from the stimulation
of lipotoxins and LPS [24]. KCs play a critical mediator
in the development of NAFLD. One of the signaling
pathways that appear to be involved in this disorder is
LPS/TLR4. Binding of LPS to TLR4 on the KC surface
activates NF-κB pathway and increases the production
and secretion of pro-inflammatory cytokines, which
recruit lymphocytes and other leukocytes [25]. It is also
reported that high accumulation of lipids in KCs induces
mitochondrial dysfunction and endoplasmic reticulum
(ER) stress [26,27]. ER stress promotes activation of the
NF-κB, JNK and CEBP pathway in KCs, and results in
insulin resistance and apoptosis.
These data suggest that KCs play a critical role in
maintain liver functions and activation of Kupffer cells
will determine their functions in liver damage and
metabolic disorder.
Recruited monocyte-derived macrophages (MDMs)
Previously, research on samples from patients and
mouse with liver diseases has clarified the heterogeneity
of macrophages in the liver. They distinguished the
tissue-resident macrophages (KCs) from infiltrating
macrophages called monocyte-derived macrophages
(MDMs) [10]. KCs and MDMs can be discriminated by
the origin, the differentiation, the behavior and, most
importantly, the functions on homeostasis and disease. It
has been known that KCs are established during
embryonic development from the fetal yolk-sack [28],
whereas MDMs originate from circulating adult blood
monocytes. Their function is also extraordinarily versatile,
for example, KCs respond to environmental signals from
liver tissue or blood circulation in a highly diversified
manner. But, MDMs can rapidly develop into restorative,
tissue-repairing cells in diseases environments.
As a macrophage maker in human liver, CD68 has
been proposed but non-distinct marker for Kupffer cells
[29]. Recently, CD163L was proposed as a marker for
KCs, in contrast CLEC5A is identified pro-inflammatory
MDMs [30]. In mice, Ly-6C (Gr-1) and CCR2 expression
levels is high in circulating monocytes, the precursors
for macrophages and dendritic cells, and they rapidly
infiltrated in tissue upon liver injury [31]. The human
counterparts of these monocyte subsets are termed
classical (CD14, CD162) [32]. Upon liver damage or
injury, Ly-6Chi MDMs are hugely recruited to the liver
and prevail the macrophage pool in mice [33]. Although
these monocyte-derived macrophages initially play pro-
inflammatory and anti-inflammatory actions, they adjust
for tissue repair and injury resolution. The immerse
infiltration of MDMs is a characteristic feature of liver
damage or injury in humans [34].
Recent studies have been distinguished the hepatic
macrophages by various cell surface markers that
infiltrated MDMs play the critical role in orchestrating
liver fibrosis progression. However, different subsets of
infiltrated MDMs play opposite roles in liver fibrosis. In
the early phase of tissue damage or injury, increment of
CCL2 expression recruits CCR2hi/Ly-6Chi monocytes in
liver tissue [35]. The infiltrated Ly-6Chi monocytes
differentiate into pro-inflammatory macrophages, and
they directly interact with hepatic stellate cells (HSCs).
HSCs produces pro-fibrotic cytokine, TGFβ and accelerate
hepatic fibrosis [6]. It suggests a pro-fibrotic function of
the Ly-6Chi hepatic macrophages. In contrast, increased
phagocytosis of macrophages assists the phenotypic
switch of the subsets, Ly-6Chi macrophages to Ly-6Clow
macrophages [36]. The Ly-6Clow macrophages produce
Metrix Metalloproteases (MMPs) and orchestrates the
resolution of liver fibrosis [37]. The finding supports for
the anti-fibrotic function of the hepatic macrophages.
These data propose that infiltrated MDMs play a critical
role in liver homeostasis and diseases and need to be
further study.
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Involvement of hepatic macrophages in progression
of Nonalcoholic Fatty Liver Disease and Nonalcoholic
Steatohepatitis
The hallmark of NAFLD is an excess of fatty acids
and accumulation of lipids in the liver. They result in
lipotoxicity to induce liver damage and injury [25,38].
These lipid-induced liver damage signals are the initiator
for dramatic expansion of hepatic macrophages because
of the massive influx of monocytes into the liver. It was
reported that cholesterol crystals in the livers progress
both human and mouse NASH [39]. KCs take up
cholesterol-rich lipoproteins using scavenger receptors
[40]. Lipid accumulated KCs recruit CD4+ T lymphocytes
and increase T cell tolerance [19]. Cholesterol crystals
also activate NLR proteins (NLRP) in LPS-exposed
KCs [41]. Recently, low-density lipoprotein cholesterol
formed cholesterol crystals on the lipid droplet membrane
of hepatocytes and activated THP1 macrophage cells
that upregulated TNF-α, NLRP3, and IL-1β mRNA
[42]. It suggested that reduction of cholesterol levels
result in resolution of NASH through dissolution of
cholesterol crystals and disperse KC structures.
In addition to lipotoxicity, hepatocyte cell death is a
critical process in NAFLD and NASH. Death receptors,
such as TNF receptors, FAS, and TRAIL receptors, have
been shown to mediate inflammatory signaling [43,44].
Cells undergoing necrosis and apoptosis release damage
associated molecular pattern (DAMP) [45], which further
accelerate inflammation by activating inflammasomes
[46]. The activation of NLRP cause the assembly of the
inflammasome complex, which contains caspase-1,
propagating inflammation and cell death by cleavage of
prointerleukins into their interleukin form, such as IL-
1β, IL-18 [47,48]. The inflammasomes are a critical in
the progression to NASH, leading to fibrosis and
cirrhosis. The DAMP associated with M1 macrophages
secrete high motility group box 1 (HMGB1), heat shock
proteins and also breakdown products of extracellular
matrix. Apoptosis is increased in hepatic cells as a result
of excess lipid-uptake [49]. Saturated fatty acids induces
hepatocyte damage by multiple mechanisms. Excess
accumulation of lipids cause lipotoxicity, which occur
lipotoxic stress in the endoplasmic reticulum and
mitochondria, thereby leading apoptosis induction of
hepatocytes [50,51]. ER stress related proteins, such as
IRE1, PERK, and ATF6 upregulate p53, which induces
the expression of BAX and the release of cytochrome C
from mitochondria result in apoptotic death [52].
In the progression of deteriorating conditions from
NAFLD to NASH, cells release stress signals. Especially,
hepatocytes undergoing necrosis release DAMP and
chemo-attractants and recruit and activates various
immune cells to the liver, initiating a wound healing &
repair responses by fibroinflammatory reactions [45].
This inflammatory response can boost to lead fibrosis
and cirrhosis. In this process, several cytokines and
chemokines, such as TNF-α, IL-1β, IL-12, IL-23, IL-6,
CCL2, and CCL5 are released in liver [35]. The
accumulation of these cytokines in liver accelerate
further the release of DAMP, promoting further
hepatocyte damage, activating and recruiting leukocytes
to further increase the inflammatory response in the
fibroinflammatory process.
Resident KCs are important in the response by rapid
producing cytokines and chemokines, such as tumor
necrosis factor (TNF)α, IL-1β, CCL2, and CCL5, which
promote the recruitment of other immune cells, such as
monocytes [35,53]. For example, in mouse models of
CCL4-induced liver fibrosis, the infiltrated monocytes
are dominated by the Ly-6Chi subset, after transmigration
into the liver, the Ly-6Chi monocytes differentiate into
Ly-6Chi macrophages. Other study suggested that the
tissue micro-environmental factors during NAFLD
process could promote the switch of Ly-6Chi macrophages
into Ly-6Chi macrophages [36]. It is important to target
hepatic macrophages for hepatic disease therapy, we
have to understanding the respective role of hepatic
macrophages, resident KCS and infiltrated Ly-6Chi and
Ly-6Clow macrophages in various types of liver diseases.
KC are activated by CD14, when presence of LPS
activates TLR4 signaling pathway. It was reported that
high expression of CD14 increases the sensitivity to LPS
in cells [54]. KCs are also activated by NF-κB, MAPK,
ERK1, p38, JNK, and IRF3 signaling pathway [55]. In
NAFLD and NASH, a high expression of TLR4 results
in massive release of cytokines, and thus contributes to
progression of inflammation and fibrosis [56].
The recruitment of Ly-6Chi bone marrow-derived
monocytes has been shown to be a critical event for the
promotion of NAFLD and NASH. The chemokine
interactions, such as CCL1-CCR8, CCL2-CCR2, CCL5-
CCR5, and CXCL10-CXCR3, have been shown to
recruit monocytes as well. These bone marrow-derived
monocytes collaborate with KCs to promote inflammation,
inducing chemokines and cytokines such as TNF-α and
IL-1β [8,10,34].
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Chemokine receptor CXCR3, a CXCL10 receptor,
mediates bone marrow-derived monocytes infiltration
and secretion of inflammatory cytokines [57]. CCL2 and
CCL5 from macrophages activate HSCs leading to
fibrosis. TNF-α has been shown to be a crucial factor for
NASH by promoting bone marrow-derived monocytes
infiltration. TNF-α can activate apoptosis and necroptosis
through death receptors, and also NF-κB pathway to
promote inflammasome, thereby accelerating inflammation.
TNF-α alienates adiponectin, an anti-inflammatory
adipokine, and then induces inflammation and insulin
resistance [58]. The increment of TNF-α has a key role
in the progression of NASH by promoting this inflammation.
Neutrophils have presented an important role in
activation of hepatic macrophages and NASH progression
[59]. Activation of TLR4 signaling on hepatic macrophages
increases neutrophil adhesion in liver sinusoids [60].
Neutrophils also promotes further recruitment of
macrophages using an antigen presenting method.
Additionally, neutrophils accelerate fibrosis by activation
and increment of proliferation of HSCs [61,62].
Conclusion
It has been become distinct that hepatic macrophages
are a critical to initiating and propagating hepatic
inflammation to progress NDFLD and NASH and is
summarized in Figure 1. Targeting hepatic macrophages
seems to be a promising therapeutic approach to care
liver diseases, such as NAFLD and NASH. Now, many
therapeutic options and trial are developing and
discovering to treat NAFLD and NASH by targeting
macrophages.
However, there are still need to be overcome in
targeting human liver macrophages. Firstly, we have to
distinguish the differences between mouse models and
humans, although there is substantial similarity.
Experimental conditions of mice are not the same as
human diseases. Moreover, many of the therapies
improve fibrosis, but not fully overwhelm NASH.
Therefore, although the clinical implications of fibrosis
resolution are very beneficial, the need to find a more
encompassing treatment remains. There remains many
points in the molecular mechanisms of NAFLD and
NASH that can be deliberated and explored for their
therapeutic potentials. Targeting macrophages to threat
NAFLD and NASH in its early progress stages may be
a superior method to reduce the damage, compared to do
it on later stages of NASH and cirrhosis.
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